Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18353144 | 0.94 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4HCAR2 | |
| SCHEMBL18355353 | 0.93 | ATM (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4HCAR2 | |
| SCHEMBL18353216 | 0.87 | ATM (0.59) | CHRNB2CHRNB4CHRNA3CHRNA4HCAR2 | |
| SCHEMBL17187306 | 0.84 | HCAR2 (0.68) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL16674069 | 0.82 | ACHE (0.60) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL18355147 | 0.81 | HCAR2 (0.52) | CHRNB2CHRNA4HCAR2KEAP1NFE2L2 | |
| SCHEMBL7954444 | 0.79 | TSHR (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL18355229 | 0.79 | L3MBTL1 (0.46) | HCAR2KEAP1NFE2L2ATMACHE | |
| SCHEMBL18364149 | 0.79 | HCAR2 (0.45) | HCAR2KEAP1NFE2L2ATMMAPT | |
| Tegomil Fumarate SCHEMBL17187305 | 0.78 | HCAR2 (0.59) | HCAR2KEAP1NFE2L2ATMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | CHRNB2 2170/4885CHRNB4 2401/4885CHRNA3 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.